Bio-Rad Laboratories (BIO) Set to Announce Quarterly Earnings on Thursday

Bio-Rad Laboratories (NYSE:BIO) will announce its earnings results after the market closes on Thursday, November 1st. Analysts expect the company to announce earnings of $1.16 per share for the quarter.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Tuesday, August 7th. The medical research company reported $1.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.37. Bio-Rad Laboratories had a return on equity of 4.23% and a net margin of 44.77%. The company had revenue of $575.91 million for the quarter, compared to the consensus estimate of $551.05 million. On average, analysts expect Bio-Rad Laboratories to post $6 EPS for the current fiscal year and $8 EPS for the next fiscal year.

BIO stock opened at $265.92 on Tuesday. The company has a current ratio of 4.50, a quick ratio of 3.17 and a debt-to-equity ratio of 0.09. Bio-Rad Laboratories has a 52-week low of $214.44 and a 52-week high of $345.15. The company has a market cap of $8.02 billion, a price-to-earnings ratio of 64.86, a price-to-earnings-growth ratio of 2.81 and a beta of 0.96.

Several equities research analysts have issued reports on BIO shares. Barclays started coverage on Bio-Rad Laboratories in a report on Wednesday, September 5th. They set an “equal weight” rating and a $345.00 price objective on the stock. Jefferies Financial Group restated a “buy” rating and set a $420.00 price objective on shares of Bio-Rad Laboratories in a report on Monday, September 24th. Morgan Stanley began coverage on Bio-Rad Laboratories in a report on Thursday, September 20th. They set an “equal weight” rating and a $335.00 price objective on the stock. Zacks Investment Research downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, August 13th. Finally, Goldman Sachs Group began coverage on Bio-Rad Laboratories in a report on Wednesday, October 17th. They issued a “buy” rating and a $350.00 price target for the company. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $342.71.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Featured Story: Should You Consider an Index Fund?

Earnings History for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with's FREE daily email newsletter.

Leave a Reply